pharmaphorum
MARCH 29, 2022
With the rapid onset of the pandemic, the race to develop a viable vaccine quickly became a race to secure access to the developed vaccines. In this article, Ben Hargreaves examines how wealth determined the winners and what is now underway to help lower-income countries gain access to the available vaccines.
European Pharmaceutical Review
SEPTEMBER 21, 2022
Biosimilar medicine Ximluci (ranibizumab) for the treatment of neovascular age-related macular degeneration, a progressive retinal macular disease, causing gradual vision impairment, mainly in the elderly population. Adapted vaccines Comirnaty Original/Omicron BA.1 Adapted vaccines Comirnaty Original/Omicron BA.1
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
NOVEMBER 14, 2022
Four medicines recommended for approval in the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP)’s latest meeting included a biosimilar for osteoporosis and a novel COVID-19 vaccine. COVID-19 update. 5 in children five to 11 years. CHMP’s safety update.
European Pharmaceutical Review
JULY 1, 2024
the CHMP gave a positive opinion for the first nasally administered emergency treatment for allergic reactions” A positive opinion was granted to the mResvia (Respiratory Syncytial Virus (RSV) mRNA vaccine). Eurneffy (epinephrine) offers an alternative method to the standard injection method of administration. 1 virus variant.
European Pharmaceutical Review
FEBRUARY 26, 2024
At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines.
pharmaphorum
DECEMBER 15, 2020
“Now more than ever, it is our responsibility as a sector to ensure affordable access to healthcare and enable the future longevity of medicine development and supply.”. The generics medicines sector can, too, play a substantial part in discovering new areas for licensed products to be used in. Delivery of essential medicines.
pharmaphorum
OCTOBER 17, 2022
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga ( TAK-003 ). Medicines submitted under EU-M4all are assessed by the CHMP in collaboration with the WHO and target countries.
Expert insights. Personalized for you.
95 
Let's personalize your content